Shots:
- The NMPA has approved iza-bren (izalontamab brengitecan) for the treatment of adult pts with recurrent or metastatic ESCC whose disease has progressed following prior Pt-based CT & PD-1/PD-L1 inhibitor therapy
- Approval was based on the P-III (PANKU-Esophagus01) trial assessing iza-bren vs CT in the above-mentioned pts (n=497) across China, which met its dual 1EP of PFS & OS at the interim analysis
- Trial showed mOS of 9.8 vs 7.2mos., and mPFS of 4.2 vs 2mos. (by BICR), with favorable safety; data were presented at ASCO’26
Ref: PRnewswire | Image: SystImmune | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
